Document is current
Any future updates will be listed below
-
Authors
Ito, Yuta https://orcid.org/0000-0001-7259-4870
Shimono, Joji
Kawamoto, Keisuke
Hatanaka, Kanako C.
Kogure, Yasunori https://orcid.org/0000-0003-1158-5131
Tabata, Mariko https://orcid.org/0000-0002-8013-7327
Saito, Yuki https://orcid.org/0000-0003-2686-9604
Mizuno, Kota
Horie, Sara https://orcid.org/0000-0001-8668-4623
Mizukami, Yosuke
Koya, Junji
Murakami, Koichi
Teshima, Takanori https://orcid.org/0000-0002-0941-271X
Hatanaka, Yutaka https://orcid.org/0000-0003-3128-1477
Chiba, Kenichi
Okada, Ai
Shiraishi, Yuichi
Miyoshi, Hiroaki https://orcid.org/0000-0002-2356-3725
Matsuno, Yoshihiro
Ohshima, Koichi
Kataoka, Keisuke https://orcid.org/0000-0002-8263-9902
Nakagawa, Masao https://orcid.org/0000-0002-8602-6054
- License Information
-
More Information
Article History
Received: 20 May 2024
Revised: 17 April 2025
Accepted: 22 April 2025
First Online: 2 May 2025
Competing interests
: K.C.H. has received research funding from NEC Corporation, Eli Lilly, and SEKISUI CHEMICAL. Y.K. has received honoraria from Kyowa Kirin, Nippon Shinyaku, Daiichi Sankyo, and Takeda Pharmaceutical. J.K. has received honoraria from TOMY DIGITAL BIOLOGY, Scrum, and Eisai. T.T. has received honoraria from Astellas Pharma, AstraZeneca, Kyowa-Kirin, SymBio Pharmaceuticals, Sumitomo Pharma, Nippon Shinyaku, Novartis, Janssen Pharmaceutical, and Bristol-Myers Squibb; has received research grants from Asahi Kasei Pharma, Eisai, Ono Pharmaceutical, Kyowa-Kirin, Shionogi, Sumitomo Pharma, Chugai Pharmaceutical, and Nippon Shinyaku; and has received research funding from Astellas Pharma, Otsuka Pharmaceutical, LUCA Science, and Priothera SAS. Y.H. has received honoraria from Eli Lilly, Daiichi Sankyo, AstraZeneca, Merck, Novartis, and Merck Sharp & Dohme; has received research funding from NEC Corporation, Eli Lilly, Shionogi, Daiichi Sankyo, and Sysmex; and has received consultancy fee from NEC Corporation. K.Kataoka has received honoraria from Ono Pharmaceutical, Eisai, Astellas Pharma, Novartis, Chugai Pharmaceutical, AstraZeneca, Sumitomo Pharma, Kyowa Kirin, Janssen Pharmaceutical, Takeda Pharmaceutical, Otsuka Pharmaceutical, SymBio Pharmaceuticals, Bristol Myers Squibb, Pfizer, Nippon Shinyaku, Daiichi Sankyo, Alexion Pharmaceuticals, AbbVie, Meiji Seika Pharma, Sanofi, Sysmex, Mundipharma, Incyte Corporation, and Kyorin Pharmaceutical; has received research funding from Asahi Kasei Pharma, Eisai, Otsuka Pharmaceutical, Ono Pharmaceutical, Kyowa Kirin, Shionogi, Takeda Pharmaceutical, Sumitomo Dainippon Pharma, Chugai Pharmaceutical, Teijin Pharma, Japan Blood Products Organization, Mochida Pharmaceutical, JCR Pharmaceuticals, Nippon Shinyaku, Chordia Therapeutics, and Meiji Seika Pharma; holds individual stocks in Asahi Genomics; and has a patent for Genetic alterations as a biomarker in T-cell lymphomas licensed to Kyoto University and PD-L1 abnormalities as a predictive biomarker for immune checkpoint blockade therapy licensed to Kyoto University. M.N. has received honoraria from Takeda Pharmaceutical, Meiji Seika Pharma, AstraZeneca, and Mundipharma; and has received research funding from Takeda Pharmaceutical and AbbVie. All remaining authors have declared no conflicts of interest.
